Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines

Lalitha V. Ramanathapuram, Tobias Hahn, Michael W. Graner, Emmanuel Katsanis, Emmanuel T. Akporiaye

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Alpha tocopheryl succinate (α-TOS) is a non-toxic vitamin E analog under study for its anti-cancer properties. In an earlier study, we showed that α-TOS, when used in combination with non-matured dendritic cells (nmDC) to treat pre-established tumors, acts as an effective adjuvant. In this study, we have used vesiculated α-TOS (Vα-TOS), a more soluble form of α-TOS that is relevant for clinical use, in combination with dendritic cells to treat pre-established murine tumors. We demonstrate that Vα-TOS kills tumor cells in vitro and inhibits the growth of pre-established murine lung carcinoma (3LLD122) as effectively as α-TOS. The combination of Vα-TOS plus non-matured or TNF-α-matured DC is more effective at inhibiting the growth of established tumors than Vα-TOS alone. We also observed that Vα-TOS induces expression of heat shock proteins in tumor cells and that co-incubation of non-matured DC with lysate derived from Vα-TOS-treated tumor cells leads to DC maturation evidenced by up-regulation of co-stimulatory molecules and secretion of IL-12p70. This study therefore demonstrates the immunomodulatory properties of Vα-TOS that may account for its adjuvant effect when combined with DC vaccines to treat established tumors.

Original languageEnglish (US)
Pages (from-to)166-177
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume55
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Succinic Acid
Dendritic Cells
Vaccines
Neoplasms
Growth
Heat-Shock Proteins
Vitamin E
Up-Regulation
Carcinoma
Lung

Keywords

  • α-tocopheryl succinate
  • Dendritic cell
  • Heat shock proteins
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. / Ramanathapuram, Lalitha V.; Hahn, Tobias; Graner, Michael W.; Katsanis, Emmanuel; Akporiaye, Emmanuel T.

In: Cancer Immunology, Immunotherapy, Vol. 55, No. 2, 02.2006, p. 166-177.

Research output: Contribution to journalArticle

Ramanathapuram, Lalitha V. ; Hahn, Tobias ; Graner, Michael W. ; Katsanis, Emmanuel ; Akporiaye, Emmanuel T. / Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. In: Cancer Immunology, Immunotherapy. 2006 ; Vol. 55, No. 2. pp. 166-177.
@article{72f9e94749ce41e8830176f4f49e990d,
title = "Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines",
abstract = "Alpha tocopheryl succinate (α-TOS) is a non-toxic vitamin E analog under study for its anti-cancer properties. In an earlier study, we showed that α-TOS, when used in combination with non-matured dendritic cells (nmDC) to treat pre-established tumors, acts as an effective adjuvant. In this study, we have used vesiculated α-TOS (Vα-TOS), a more soluble form of α-TOS that is relevant for clinical use, in combination with dendritic cells to treat pre-established murine tumors. We demonstrate that Vα-TOS kills tumor cells in vitro and inhibits the growth of pre-established murine lung carcinoma (3LLD122) as effectively as α-TOS. The combination of Vα-TOS plus non-matured or TNF-α-matured DC is more effective at inhibiting the growth of established tumors than Vα-TOS alone. We also observed that Vα-TOS induces expression of heat shock proteins in tumor cells and that co-incubation of non-matured DC with lysate derived from Vα-TOS-treated tumor cells leads to DC maturation evidenced by up-regulation of co-stimulatory molecules and secretion of IL-12p70. This study therefore demonstrates the immunomodulatory properties of Vα-TOS that may account for its adjuvant effect when combined with DC vaccines to treat established tumors.",
keywords = "α-tocopheryl succinate, Dendritic cell, Heat shock proteins, Immunotherapy, Vaccine",
author = "Ramanathapuram, {Lalitha V.} and Tobias Hahn and Graner, {Michael W.} and Emmanuel Katsanis and Akporiaye, {Emmanuel T.}",
year = "2006",
month = "2",
doi = "10.1007/s00262-005-0016-7",
language = "English (US)",
volume = "55",
pages = "166--177",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines

AU - Ramanathapuram, Lalitha V.

AU - Hahn, Tobias

AU - Graner, Michael W.

AU - Katsanis, Emmanuel

AU - Akporiaye, Emmanuel T.

PY - 2006/2

Y1 - 2006/2

N2 - Alpha tocopheryl succinate (α-TOS) is a non-toxic vitamin E analog under study for its anti-cancer properties. In an earlier study, we showed that α-TOS, when used in combination with non-matured dendritic cells (nmDC) to treat pre-established tumors, acts as an effective adjuvant. In this study, we have used vesiculated α-TOS (Vα-TOS), a more soluble form of α-TOS that is relevant for clinical use, in combination with dendritic cells to treat pre-established murine tumors. We demonstrate that Vα-TOS kills tumor cells in vitro and inhibits the growth of pre-established murine lung carcinoma (3LLD122) as effectively as α-TOS. The combination of Vα-TOS plus non-matured or TNF-α-matured DC is more effective at inhibiting the growth of established tumors than Vα-TOS alone. We also observed that Vα-TOS induces expression of heat shock proteins in tumor cells and that co-incubation of non-matured DC with lysate derived from Vα-TOS-treated tumor cells leads to DC maturation evidenced by up-regulation of co-stimulatory molecules and secretion of IL-12p70. This study therefore demonstrates the immunomodulatory properties of Vα-TOS that may account for its adjuvant effect when combined with DC vaccines to treat established tumors.

AB - Alpha tocopheryl succinate (α-TOS) is a non-toxic vitamin E analog under study for its anti-cancer properties. In an earlier study, we showed that α-TOS, when used in combination with non-matured dendritic cells (nmDC) to treat pre-established tumors, acts as an effective adjuvant. In this study, we have used vesiculated α-TOS (Vα-TOS), a more soluble form of α-TOS that is relevant for clinical use, in combination with dendritic cells to treat pre-established murine tumors. We demonstrate that Vα-TOS kills tumor cells in vitro and inhibits the growth of pre-established murine lung carcinoma (3LLD122) as effectively as α-TOS. The combination of Vα-TOS plus non-matured or TNF-α-matured DC is more effective at inhibiting the growth of established tumors than Vα-TOS alone. We also observed that Vα-TOS induces expression of heat shock proteins in tumor cells and that co-incubation of non-matured DC with lysate derived from Vα-TOS-treated tumor cells leads to DC maturation evidenced by up-regulation of co-stimulatory molecules and secretion of IL-12p70. This study therefore demonstrates the immunomodulatory properties of Vα-TOS that may account for its adjuvant effect when combined with DC vaccines to treat established tumors.

KW - α-tocopheryl succinate

KW - Dendritic cell

KW - Heat shock proteins

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=27944499761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944499761&partnerID=8YFLogxK

U2 - 10.1007/s00262-005-0016-7

DO - 10.1007/s00262-005-0016-7

M3 - Article

C2 - 16041582

AN - SCOPUS:27944499761

VL - 55

SP - 166

EP - 177

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -